Showing results (141-150 of 162) with videos related to
Sort By:
Pageof 17
Blood|September 17, 2005
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cellsThomas Strömberg, Simon Ekman, Leonard Girnita, et al.Acta Pharmacologica Sinica|April 9, 2013
Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivoSong Xu, Kim De Veirman, Holly Evans, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|November 20, 2008
Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myelomaDeborah J Heath, Andrew D Chantry, Clive H Buckle, et al.Journal of Hematology & Oncology|November 8, 2024
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stagesEmma Verheye, Daliya Kancheva, Hatice Satilmis, et al.Oncotarget|April 21, 2016
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myelomaRoy Heusschen, Joséphine Muller, Marilène Binsfeld, et al.The American Journal of Pathology|August 28, 2004
Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse modelEls Van Valckenborgh, Peter I Croucher, Hendrik De Raeve, et al.International Journal of Cancer|January 19, 2007
Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivoClaire M Edwards, Gabrielle Mueller, Anke J Roelofs, et al.Oncotarget|March 24, 2018
Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical studyLuigia Rao, Kim De Veirman, Donato Giannico, et al.Molecular Cancer Therapeutics|October 20, 2021
The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide TherapyJanik Puttemans, Benoit Stijlemans, Marleen Keyaerts, et al.Cancer Research|September 7, 2012
Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse modelPedram Kharaziha, Hendrik De Raeve, Charlotte Fristedt, et al.Pageof 17